Lakewood-Amedex Biotherapeutics Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.9M
- Price
- $2.20
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.08%
- Volume
- 16.5K
About
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
Quick stats
Shares outstanding1.8M
Computed float1.6M
Float / shares94.0%
Cash runway (months)-4.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002079272
AI Summary
AI-generated1/17
minorbullishclinical trial
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Lakewood-Amedex highlighted resistance data for Nu-3, a Phase 2-ready candidate for infected diabetic foot ulcers, in alignment with the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria.
The company reported that Nu-3 demonstrated a high barrier to resistance in serial passage experiments and broad spectrum activity against various resistant strains including MRSA and VRE.
CEO Kelvin Cooper noted that the platform's physical mechanism of action directly addresses the global crisis of antimicrobial resistance.